Publications

Towards a Multi-sectoral Approach to Population Health: A Scoping Review of Cross-sectoral Evaluations of Health Interventions.

Koleva-Kolarova R. et al, (2026), Appl Health Econ Health Policy

Roux-en-Y gastric bypass, adjustable gastric banding or sleeve gastrectomy for severe obesity: The By-Band-Sleeve randomised controlled trial.

(2026), Health Technol Assess, 30, 1 - 224

HERC database of mapping studies, Version 10.0

DAKIN H. et al, (2025)

Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial.

By-Band-Sleeve Collaborative Group ., (2025), Lancet Diabetes Endocrinol, 13, 410 - 426

Genetic-Guided Pharmacotherapy for Coronary Artery Disease: A Systematic and Critical Review of Economic Evaluations.

Lim KK. et al, (2024), J Am Heart Assoc, 13

protocol for mobilising novel finance models for collaborative health promotion and disease prevention initiatives: taking a smart capacitating investment approach in the Invest4Health project.

Lane J. et al, (2024), Front Public Health, 12

HERC database of mapping studies, Version 9.0

DAKIN H. et al, (2023)

Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.

Liao W. et al, (2023), Lancet Respir Med, 11, 685 - 697

Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.

Nagy B. et al, (2023), Per Med, 20, 401 - 411

Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation.

Koleva-Kolarova R. et al, (2023), Per Med, 20, 305 - 319

Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems.

Koleva-Kolarova R. et al, (2023), Per Med, 20, 357 - 374

Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.

Koleva-Kolarova R. et al, (2023), Per Med, 20, 339 - 355

Cost-effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries.

Szilberhorn L. et al, (2023), Per Med, 20, 387 - 399

Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.

Kovács G. et al, (2023), Per Med, 20, 375 - 385

Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries.

Vellekoop H. et al, (2023), Per Med, 20, 321 - 338

Search results (43)